Bacillus Calmette-Guérin-Induced Trained Immunity Is Not Protective for Experimental Influenza A/Anhui/1/2013 (H7N9) Infection in Mice

Frontiers in Immunology
Charlotte L C J de BreeJohn Dulos

Abstract

Avian influenza A of the subtype H7N9 has been responsible for almost 1,600 confirmed human infections and more than 600 deaths since its first outbreak in 2013. Although sustained human-to-human transmission has not been reported yet, further adaptations to humans in the viral genome could potentially lead to an influenza pandemic, which may have severe consequences due to the absence of pre-existent immunity to this strain at population level. Currently there is no influenza A (H7N9) vaccine available. Therefore, in case of a pandemic outbreak, alternative preventive approaches are needed, ideally even independent of the type of influenza virus outbreak. Bacillus Calmette-Guérin (BCG) is known to induce strong heterologous immunological effects, and it has been shown that BCG protects against non-related infection challenges in several mouse models. BCG immunization of mice as well as human induces trained innate immune responses, resulting in increased cytokine responses upon subsequent ex vivo peripheral blood mononuclear cell restimulation. We investigated whether BCG (Statens Serum Institut-Denmark)-induced trained immunity may protect against a lethal avian influenza A/Anhui/1/2013 (H7N9) challenge. Here, we show that is...Continue Reading

Associated Clinical Trials

References

Jun 20, 2001·Journal of Virology·G F RimmelzwaanA D Osterhaus
Apr 17, 2009·Vaccine·Rebecca J CoxLars R Haaheim
Dec 23, 2011·The Pediatric Infectious Disease Journal·Sofie Biering-SørensenChristine Stabell Benn
Jun 20, 2012·Current Opinion in Virology·T KuikenG F Rimmelzwaan
Sep 19, 2012·Proceedings of the National Academy of Sciences of the United States of America·Johanneke KleinnijenhuisMihai G Netea
May 18, 2013·Trends in Immunology·Christine S BennPeter Aaby
Nov 7, 2013·Journal of Innate Immunity·Johanneke KleinnijenhuisMihai G Netea
Dec 25, 2013·Proceedings of the National Academy of Sciences of the United States of America·Zhongfang WangJianqing Xu
Oct 8, 2014·JAMA : the Journal of the American Medical Association·Mark J MulliganUNKNOWN DMID 13-0032 H7N9 Vaccine Study Group
Dec 8, 2016·Cell Reports·Rob J W ArtsMihai G Netea
Oct 4, 2017·The Journal of Infectious Diseases·Kirsty R ShortDebby van Riel
Dec 17, 2017·Immunological Reviews·Charles A Dinarello

❮ Previous
Next ❯

Citations

Nov 7, 2019·Scientific Reports·Mariana Guerra-Maupome, Jodi L McGill
May 22, 2020·European Journal of Immunology·Virgil Schijns, Ed C Lavelle
Aug 23, 2020·Journal of Medical Virology·Md Zahurul IslamMd Abdul Alim Al-Bari
Jan 9, 2019·Frontiers in Immunology·Silvia Sánchez-RamónJosé Luis Subiza
Jun 26, 2020·Frontiers in Immunology·Kristen A ByrneJodi L McGill
Nov 15, 2020·International Journal of Molecular Sciences·Kevin AdamsSteven M Johnson
Apr 2, 2021·Infection and Drug Resistance·Gopala KoneruHelal F Hetta

❮ Previous
Next ❯

Methods Mentioned

BETA
FCS
enzyme-linked immunosorbent assay
ELISA

Software Mentioned

Graphpad Prism

Related Concepts

Related Feeds

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.